Statement of Deviation & Variation for the half year ended 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astonea Labs Ltd raised ₹37.67 crore via IPO on 30 May 2025. As of 31 March 2026, the company has utilised ₹35.91 crore (95.3%), leaving ₹1.75 crore unutilised. The key deviation is a reallocation of ₹6.25 crore from the original objects to acquire an equity stake in Damaira Pharmaceuticals Private Limited, which was approved by the Board on 27 February 2026 and subsequently ratified by shareholders at an EGM on 27 March 2026. The funds were fully deployed for this acquisition on 30 March 2026. Partially unutilised categories include Bolivia registration expenses (₹66.66 lakh remaining) and general corporate purposes (₹1.09 lakh remaining). The company also changed its registered office effective 1 April 2026.
The reallocation of ₹6.25 crore toward acquiring Damaira Pharmaceuticals signals a strategic pivot toward the pharmaceutical sector, which could broaden revenue streams but introduces integration risk. The company appears fully invested in the new asset, with only ₹1.75 crore remaining unutilised.